The Inside Scoop on Biaya Perawatan Kanker Payudara di India - Wahyu Anu Kedah Dibaca!

Breast cancer accounts for 31% of all cancers diagnosed in Indian women, making it the leading type of cancer. This serious disease must be treated at an early stage for the best outcomes. Our blog breaks down the breast cancer t..

Abemaciclib, inhibitor aromatase, Eli Lilly na Company, terapi éndokrin, Tamoxifen, Verzenio

Abemaciclib kalayan terapi endokrin disatujuan ku FDA dina kanker payudara HER 2 positif

Maret 2023: Abemaciclib (Verzenio, Eli Lilly and Company) sareng terapi éndokrin (tamoxifen atanapi inhibitor aromatase) parantos disatujuan ku Administrasi Pangan sareng Narkoba (FDA) pikeun pengobatan adjuvant pasien dewasa kalayan ..

Cina, Enhertu, HER 2 positip

Enhertu geus disatujuan di Cina pikeun penderita kanker payudara métastatik HER2-positip

Feb 2023: Enhertu (trastuzumab deruxtecan) from AstraZeneca and Daiichi Sankyo has been approved as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received ..

Hamsa, Hamsa Nandini, Mirchi, pilem Mirchi

Aktor Hamsa Nandini Nyadiakeun Pembaruan Sataun Saatos Perawatan Kanker Payudara

Pebruari 2023: Hamsa Nandini, anu didiagnosis karsinoma Invasif Kelas III (Kanker Payudara) taun 2021, parantos ngapdet pengikut Instagram na ngeunaan status kaséhatan na. Aktris, anu parantos muncul dina pilem Telugu sapertos Mirchi sareng Lege..

Élmu Gilead, sacituzumab govitecan-hziy, Trodelvy, TROPiCS-02

Sacituzumab govitecan-hziy disatujuan ku FDA pikeun kanker payudara HR-positip

Pebruari 2023: Administrasi Pangan sareng Narkoba (FDA) parantos disatujuan sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) pikeun jalma anu reseptor hormon (HR) -positip, HER2-négatip (IHC 0, IHC 1+, atanapi IHC. 2+/ISH-) kanker payudara..

elastis, Orserdu, Stemline Therapeutics

Elasestrant disatujuan ku FDA pikeun ER-positip, HER2-négatip, ESR1-mutated maju atanapi kanker payudara métastatik

In February 2023, the Food and Drug Administration (FDA) approved elacestrant (Orserdu, Stemline Therapeutics, Inc.) for women or men over 50 who have advanced or metastatic breast cancer and are ER-positive, HER2-negative, and h..

Daiichi Sankyo, Enhertu, fam-trastuzumab deruktecan-nxki

Fam-trastuzumab deruxtecan-nxki disatujuan ku FDA pikeun kanker payudara

April 2022: Pasién sawawa kalayan kanker payudara HER2-positip anu teu tiasa direseksi atanapi métastatik anu parantos nampi regimen dumasar anti-HER2 sateuacanna boh dina setting métastatik, atanapi dina setting neoadjuvant atanapi adjuvant sareng parantos ngembangkeun.

AstraZeneca Pharmaceuticals, BRCA, gBRCAm, Lynparza, olaparib, OlympiA

Olaparib disatujuan pikeun pengobatan adjuvant kanker payudara awal anu résiko luhur

Maret 2022: Administrasi Pangan sareng Narkoba parantos nyatujuan olaparib (Lynparza, AstraZeneca Pharmaceuticals, LP) pikeun pengobatan adjuvant pasien dewasa anu ngarusak atanapi disangka ngarusak germline BRCA-mutated (gBRCAm) h..

Abemaciclib, Gancang, Dako Omnis, Eli Lilly na Company, terapi éndokrin, Tamoxifen, Verzenio

Abemaciclib disatujuan ku FDA kalayan terapi endokrin pikeun kanker payudara awal

Oktober 2021: Administrasi Pangan sareng Narkoba parantos nyatujuan abemaciclib (Verzenio, Eli Lilly sareng Perusahaan) dina kombinasi sareng terapi endokrin (tamoxifen atanapi inhibitor aromatase) pikeun pengobatan adjuvant pasien dewasa kalayan ho..

KEYTRUDA, Merck, Pembrolizumab, ekstensi TNBC

Pembrolizumab parantos disahkeun ku FDA pikeun kanker payudara triple-négatip résiko tingkat tinggi

Agustus 2021: Pembrolizumab (Keytruda, Merck) disatujuan ku FDA pikeun kanker payudara, résiko triple-négatip (TNBC) anu résiko tinggi, salaku pangobatan neoadjuvan dina kombinasi sareng kémoterapi, sareng engké salaku agén tunggal salaku adjuv ..